CL2013003728A1 - Anticuerpo antagonista o fragmento del mismo que se une a ox40 de humano; epitope del dominio extracelular de ox40 de humano que es unido por en anticuerpo antes mencionado; acido nucleico que codifica el anticuerpo; vector y célula hospedera que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion que comprende el anticuerpo; inmunoconjugado; uso para tratar trastornos mediados por ox40. - Google Patents

Anticuerpo antagonista o fragmento del mismo que se une a ox40 de humano; epitope del dominio extracelular de ox40 de humano que es unido por en anticuerpo antes mencionado; acido nucleico que codifica el anticuerpo; vector y célula hospedera que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion que comprende el anticuerpo; inmunoconjugado; uso para tratar trastornos mediados por ox40.

Info

Publication number
CL2013003728A1
CL2013003728A1 CL2013003728A CL2013003728A CL2013003728A1 CL 2013003728 A1 CL2013003728 A1 CL 2013003728A1 CL 2013003728 A CL2013003728 A CL 2013003728A CL 2013003728 A CL2013003728 A CL 2013003728A CL 2013003728 A1 CL2013003728 A1 CL 2013003728A1
Authority
CL
Chile
Prior art keywords
antibody
human
nucleic acid
epitope
fragment
Prior art date
Application number
CL2013003728A
Other languages
English (en)
Inventor
Antoine Attinger
Stanislas Blein
Jonathan Albert Back
Samuel Hou
Rami Lissilaa
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46601863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003728(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of CL2013003728A1 publication Critical patent/CL2013003728A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

LA INVENCIÓN PROPORCIONA A UN ANTICUERPO ANTAGONISTA O FRAGMENTO DEL MISMO QUE SE UNE A OX40 DE HUMANO; EPITOPE DEL DOMINIO EXTRACELULAR DE OX40 DE HUMANO QUE ES UNIDO POR EN ANTICUERPO ANTES MENCIONADO; ACIDO NUCLEICO QUE CODIFICA EL ANTICUERPO; VECTOR Y CÉLULA HOSPEDERA QUE COMPRENDEN DICHO ACIDO NUCLEICO; METODO PARA PRODUCIR EL ANTICUERPO; COMPOSICION QUE COMPRENDE EL ANTICUERPO; INMUNOCONJUGADO; USO PARA TRATAR TRASTORNOS MEDIADOS POR OX40.
CL2013003728A 2011-07-11 2013-12-26 Anticuerpo antagonista o fragmento del mismo que se une a ox40 de humano; epitope del dominio extracelular de ox40 de humano que es unido por en anticuerpo antes mencionado; acido nucleico que codifica el anticuerpo; vector y célula hospedera que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion que comprende el anticuerpo; inmunoconjugado; uso para tratar trastornos mediados por ox40. CL2013003728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506491P 2011-07-11 2011-07-11

Publications (1)

Publication Number Publication Date
CL2013003728A1 true CL2013003728A1 (es) 2014-10-17

Family

ID=46601863

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003728A CL2013003728A1 (es) 2011-07-11 2013-12-26 Anticuerpo antagonista o fragmento del mismo que se une a ox40 de humano; epitope del dominio extracelular de ox40 de humano que es unido por en anticuerpo antes mencionado; acido nucleico que codifica el anticuerpo; vector y célula hospedera que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion que comprende el anticuerpo; inmunoconjugado; uso para tratar trastornos mediados por ox40.

Country Status (30)

Country Link
US (6) US8748585B2 (es)
EP (1) EP2731677B1 (es)
JP (3) JP6261499B2 (es)
KR (2) KR102119840B1 (es)
CN (2) CN103717263B (es)
AP (1) AP2014007415A0 (es)
AU (2) AU2012282116B2 (es)
BR (1) BR112014000630A2 (es)
CA (2) CA2840460C (es)
CL (1) CL2013003728A1 (es)
CO (1) CO7020848A2 (es)
CY (1) CY1120414T1 (es)
DK (1) DK2731677T3 (es)
EA (1) EA036047B1 (es)
ES (1) ES2670621T3 (es)
HR (1) HRP20180858T1 (es)
HU (1) HUE037700T2 (es)
IL (1) IL259979A (es)
LT (1) LT2731677T (es)
MX (1) MX353931B (es)
PE (1) PE20142243A1 (es)
PH (1) PH12014500089A1 (es)
PL (1) PL2731677T3 (es)
PT (1) PT2731677T (es)
SI (1) SI2731677T1 (es)
SM (1) SMT201800359T1 (es)
TR (1) TR201807040T4 (es)
UA (1) UA116873C2 (es)
WO (1) WO2013008171A1 (es)
ZA (1) ZA201400254B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10196450B2 (en) 2010-08-23 2019-02-05 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ594315A (en) * 2009-02-17 2013-05-31 Ucb Pharma Sa Antibody molecules having specificity for human ox40
EP2631246B1 (en) * 2010-08-20 2016-07-20 Josai University Corporation Monoclonal antibody having immunosuppressive activity or fragment to which antigen thereof is bonded
WO2013008171A1 (en) * 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP3508215A3 (en) 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
CN105188749B (zh) 2012-12-21 2017-12-19 西雅图基因公司 抗ntb‑a抗体及相关组合物和方法
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
JP2016538275A (ja) 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
PL3116891T3 (pl) * 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
CA2942245C (en) * 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3322443A1 (en) * 2015-07-13 2018-05-23 Yeda Research and Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
SI3242890T1 (sl) * 2015-01-08 2020-01-31 BioNTech SE Agonistična sredstva, ki vežejo receptorje TNF
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
WO2017063162A1 (zh) * 2015-10-15 2017-04-20 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
CN108883173B (zh) * 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
KR20180098671A (ko) * 2016-01-11 2018-09-04 인히브릭스, 인크. 다가 및 다중특이적 ox40-결합 융합 단백질
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
UA126905C2 (uk) * 2016-06-13 2023-02-22 Ай-Маб Байофарма Юес Лімітед Антитіло до pd-l1 та його застосування
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) * 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
US11242398B2 (en) * 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
US11142579B2 (en) 2017-12-06 2021-10-12 Sorrento Therapeutics, Inc. Variant antibodies that bind OX40
CN108218990B (zh) * 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
TWI831778B (zh) * 2018-05-11 2024-02-11 澳門商同潤澳門一人有限公司 抗ox40的全人抗體及其製備方法和用途
EP3794032A1 (en) * 2018-05-18 2021-03-24 Ichnos Sciences SA Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseases
WO2019229155A1 (en) * 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
TW202035455A (zh) 2018-09-26 2020-10-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｏｘ４０抗體、其抗原結合片段及其醫藥用途
WO2020132857A1 (zh) * 2018-12-25 2020-07-02 杭州翰思生物医药有限公司 抗ox40的单克隆抗体及其应用
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN114423787B (zh) 2019-07-19 2025-01-24 昂科里斯庞斯公司 免疫调节性抗体及其使用方法
US20220273796A1 (en) * 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
IL293471A (en) 2019-12-17 2022-08-01 Amgen Inc Dual interleukin-2 / tnf receptor agonist for use in medicine
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
PE20230255A1 (es) 2020-04-17 2023-02-07 Hutchison Medipharma Ltd Anticuerpo anti-ox40 y usos del mismo
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN114685658B (zh) * 2020-12-30 2024-12-17 百力司康生物医药(杭州)有限公司 Ox40的靶向抗体及其制备方法和应用
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
KR20240139085A (ko) 2022-02-09 2024-09-20 펫메딕스 리미티드 치료 항체
IL319568A (en) 2022-09-15 2025-05-01 Avidicure Ip B V Multispecific antigen-binding proteins for NK cell stimulation and their uses
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025161898A1 (en) * 2024-02-02 2025-08-07 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ox40 antibodies and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
CN118667023B (zh) * 2024-07-16 2025-07-15 上海生物制品研究所有限责任公司 一种抗ox40抗体及其制备方法和应用
WO2026057844A1 (en) * 2024-09-16 2026-03-19 Les Laboratoires Servier Antibodies to ox40 and compositions thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5924939A (en) 1996-09-10 1999-07-20 Cobra Golf Incorporated Golf club head with a strike face having a first insert within a second insert
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
WO2004050708A2 (en) * 2002-11-29 2004-06-17 Rsr Limited Antibody for the thyrotropin receptor and uses thereof
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
MY149079A (en) * 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
PT2594590E (pt) * 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
NZ594315A (en) 2009-02-17 2013-05-31 Ucb Pharma Sa Antibody molecules having specificity for human ox40
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
EP2631246B1 (en) 2010-08-20 2016-07-20 Josai University Corporation Monoclonal antibody having immunosuppressive activity or fragment to which antigen thereof is bonded
CA2809089C (en) * 2010-08-23 2018-12-18 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
USRE50410E1 (en) * 2011-01-12 2025-04-29 Callgate Co., Ltd. System and method for providing a screen switching service during call counseling and device applied thereto
WO2013008171A1 (en) 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10196450B2 (en) 2010-08-23 2019-02-05 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
US10851173B2 (en) 2010-08-23 2020-12-01 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same

Also Published As

Publication number Publication date
PH12014500089A1 (en) 2014-02-17
EA201490053A1 (ru) 2014-08-29
MX2014000479A (es) 2014-02-17
HRP20180858T1 (hr) 2018-09-21
JP2018093869A (ja) 2018-06-21
MX353931B (es) 2018-02-02
AU2016204274A1 (en) 2016-07-14
EP2731677B1 (en) 2018-04-18
CA3158257A1 (en) 2013-01-17
EP2731677A1 (en) 2014-05-21
UA116873C2 (uk) 2018-05-25
US20200071409A1 (en) 2020-03-05
CN103717263B (zh) 2018-01-12
CY1120414T1 (el) 2019-07-10
US20250250351A1 (en) 2025-08-07
US8748585B2 (en) 2014-06-10
JP2014523248A (ja) 2014-09-11
DK2731677T3 (en) 2018-06-18
BR112014000630A2 (pt) 2017-02-14
SI2731677T1 (sl) 2018-09-28
AU2012282116A2 (en) 2014-04-10
KR20140043811A (ko) 2014-04-10
PT2731677T (pt) 2018-07-27
US20130183315A1 (en) 2013-07-18
CN107915775A (zh) 2018-04-17
SMT201800359T1 (it) 2018-09-13
CN107915775B (zh) 2022-07-12
WO2013008171A1 (en) 2013-01-17
NZ619849A (en) 2016-01-29
AU2012282116A1 (en) 2014-02-13
KR20200067220A (ko) 2020-06-11
CO7020848A2 (es) 2014-08-11
PL2731677T3 (pl) 2018-08-31
JP6261499B2 (ja) 2018-01-17
AP2014007415A0 (en) 2014-02-28
KR102119840B1 (ko) 2020-06-09
TR201807040T4 (tr) 2018-06-21
EA036047B1 (ru) 2020-09-18
HK1253936A1 (zh) 2019-07-05
IL259979A (en) 2018-07-31
ES2670621T3 (es) 2018-05-31
US20140294824A1 (en) 2014-10-02
HUE037700T2 (hu) 2018-09-28
US12281169B2 (en) 2025-04-22
CA2840460A1 (en) 2013-01-17
AU2016204274B2 (en) 2017-12-07
CN103717263A (zh) 2014-04-09
JP2019213520A (ja) 2019-12-19
US20220411526A1 (en) 2022-12-29
PE20142243A1 (es) 2015-01-11
AU2012282116B2 (en) 2016-07-07
US11407839B2 (en) 2022-08-09
LT2731677T (lt) 2018-07-10
US20170260280A1 (en) 2017-09-14
CA2840460C (en) 2022-08-16
ZA201400254B (en) 2015-05-27

Similar Documents

Publication Publication Date Title
CL2013003728A1 (es) Anticuerpo antagonista o fragmento del mismo que se une a ox40 de humano; epitope del dominio extracelular de ox40 de humano que es unido por en anticuerpo antes mencionado; acido nucleico que codifica el anticuerpo; vector y célula hospedera que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion que comprende el anticuerpo; inmunoconjugado; uso para tratar trastornos mediados por ox40.
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
BR112013029951A2 (pt) uso de anticorpos ou fragmentos de anticorpos anti-cgrp ou anti-cgrp-r para tratar ou prevenir formas de diarreia crônicas e agudas
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
CL2017002641A1 (es) Construcciones de anticuerpos biespecíficos contra cdh3 y cd3
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
CL2013002743A1 (es) Cristal de anticuerpo de igg anti-esclerostina; metodo de produccion; composicion que lo comprende; y su uso para tratar desordenes oseos.
CR20140146A (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
CO2018000976A2 (es) Constructos de anticuerpo para cd70 y cd3
CL2012002433A1 (es) Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer.
EA201492101A1 (ru) Антитела против fcrn
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
CL2015000696A1 (es) Tratamiento para artritis reumatoide
MX374826B (es) Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas.
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
MX2016002571A (es) Regulador de ph de transduccion.
MX384419B (es) Constructos de anticuerpos para cdh19 y cd3
EA201691974A1 (ru) Антитела против ox40 и способы их применения
CL2013002811A1 (es) Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.
CL2012002737A1 (es) Anticuerpo anti-cd40 humanizado; polinucleótido que lo codifica; composición farmacéutica que comprende dicho anticuerpo; y su uso para bloquear una respuesta inmunitaria mediada por cd40 humana.
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
BR112014004168A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
EA201491602A1 (ru) Стабилизирующие агенты и способы их использования
MX2016006595A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos de uso de las mismas.